Sumit Kumar Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sumit Kumar Singh has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Kajal Kachhawaha
Laboratory of Engineered Therapeutics, School of Biochemical Engineering, Indian Institute of Technology (Banaras Hindu University), Varanasi, India
3 shared publicationsRohan Shah
SCIEX India Private Limited
3 shared publicationsSantanu Singh
Laboratory of Engineered Therapeutics, School of Biochemical Engineering, Indian Institute of Technology (Banaras Hindu University), Varanasi, India
3 shared publicationsKhyati Joshi
School of Biochemical Engineering, Indian Institute of Technology (Banaras Hindu University)
2 shared publicationsNiharika Budholiya
Agilent Technologies
1 shared publicationPriyanka Nain
Department of Chemical and Bimolecular Engineering, University of Delaware, Newark, DE, USA
1 shared publication
Latest Publications
- 24 May 2024
- Published by Elsevier in Biochemical Pharmacology
- Vol. 225, 116303
Comprehensive approaches to preclinical evaluation of monoclonal antibodies and their next-generation derivatives
- 24 May 2024
- Published by Elsevier in Biochemical Pharmacology
- Vol. 225, 116303
Comprehensive approaches to preclinical evaluation of monoclonal antibodies and their next-generation derivatives
- 1 January 2024
- Published by Springer Nature
- p. 1-19
Experimental Design in Proteomic Mass Spectrometry Studies for Biomarker Discovery
- 1 January 2024
- Published by Springer Nature
- p. 1-19
Experimental Design in Proteomic Mass Spectrometry Studies for Biomarker Discovery
- 1 January 2024
- Published by Springer Nature
- p. 65-85
Comparative Analysis of Shotgun and Targeted Proteomics: Insights for Biomarker Research
- 1 January 2024
- Published by Springer Nature
- p. 65-85
Comparative Analysis of Shotgun and Targeted Proteomics: Insights for Biomarker Research
- 1 January 2024
- Published by Springer Nature
- p. 21-43
Clinical Sample Considerations in Proteomics-Based Biomarker Studies: Advancing Precision Medicine
- 1 January 2024
- Published by Springer Nature
- p. 21-43
Clinical Sample Considerations in Proteomics-Based Biomarker Studies: Advancing Precision Medicine
- 19 December 2022
- Published by Taylor & Francis in Preparative Biochemistry & Biotechnology
- Vol. 53 (7) , 728-752
Bioprocessing of recombinant proteins from Escherichia coli inclusion bodies: insights from structure-function relationship for novel applications
The formation of inclusion bodies (IBs) during expression of recombinant therapeutic proteins using E. coli is a significant hurdle in producing high-quality, safe, and efficacious medicines. The improved understanding of the structure-function relationship of the IBs has resulted in the development of novel biotechnologies that have streamlined the isolation, solubilization, refolding, and purification of the active functional proteins from the bacterial IBs. Together, this overall effort promises to radically improve the scope of experimental biology of therapeutic protein production and expand new prospects in IBs usage. Notably, the IBs are increasingly used for applications in more pristine areas such as drug delivery and material sciences. In this review, we intend to provide a comprehensive picture of the bio-processing of bacterial IBs, including assessing critical gaps that still need to be addressed and potential solutions to overcome them. We expect this review to be a useful resource for those working in the area of protein refolding and therapeutic protein production.
- 19 December 2022
- Published by Taylor & Francis in Preparative Biochemistry & Biotechnology
- Vol. 53 (7) , 728-752
Bioprocessing of recombinant proteins from Escherichia coli inclusion bodies: insights from structure-function relationship for novel applications
The formation of inclusion bodies (IBs) during expression of recombinant therapeutic proteins using E. coli is a significant hurdle in producing high-quality, safe, and efficacious medicines. The improved understanding of the structure-function relationship of the IBs has resulted in the development of novel biotechnologies that have streamlined the isolation, solubilization, refolding, and purification of the active functional proteins from the bacterial IBs. Together, this overall effort promises to radically improve the scope of experimental biology of therapeutic protein production and expand new prospects in IBs usage. Notably, the IBs are increasingly used for applications in more pristine areas such as drug delivery and material sciences. In this review, we intend to provide a comprehensive picture of the bio-processing of bacterial IBs, including assessing critical gaps that still need to be addressed and potential solutions to overcome them. We expect this review to be a useful resource for those working in the area of protein refolding and therapeutic protein production.